Ranbaxy scrambles to fix problems that challenge its exclusives

Eric Palmer

In an effort to get itself into a place where it can again ship from its FDA-approved plants in India, Laboratories says it is taking a hard look at how it runs its API operations.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS